AbCellera Biologics Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Carl Hansen
- Full Time Employees
- 562
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 150 W 4th Ave Vancouver BC Canada V5Y 0A1
- IPO Date
- Dec 11, 2020
- CIK
- 0001703057
- Website
- abcellera.com
- Similar Companies
- Business
- AbCellera Biologics Inc. (ABCL) is a biotechnology company that discovers and develops antibody-based therapeutics using proprietary AI-powered platforms for target discovery, antibody discovery, and optimization. The company offers integrated services including de novo antibody discovery from immune cells; computational protein design and engineering; and GPCR and ion channel screening technologies, with key partnerships supporting programs in oncology, metabolic and endocrine conditions, and autoimmune diseases. AbCellera operates primarily in North America and Europe, serving pharmaceutical and biotechnology partners; it was founded in 2012 and is headquartered in Vancouver, Canada. Core products and services encompass the AbCellera Engine platform, which combines microfluidics, deep learning AI, and single-cell analysis for rapid antibody isolation; proprietary FC Sort and FC Nano technologies for high-throughput functional screening; and end-to-end development support from discovery to preclinical candidates, including bispecific antibodies and antibody-drug conjugates under brands like those partnered with Eli Lilly and Novartis. The company targets large-molecule therapeutics across immunology, neurodegeneration, and infectious diseases, with a pipeline featuring wholly-owned assets such as ABCL635 for metabolic disorders and partnered programs advancing in Phase 1 trials. In the last 1-2 years, AbCellera expanded its strategic alliances, including a major multi-target collaboration with AbbVie in 2024 for immunology and neuroscience antibodies; launched new proprietary programs like ABCL575 targeting T-cell mediated autoimmune diseases; and completed a $225 million strategic financing round in late 2024 led by existing partners to fuel internal pipeline advancement and AI platform enhancements. The company also advanced clinical milestones, with partner Eli Lilly dosing first patients in Phase 1 for bebtelovimab follow-ons and initiating new GPCR-focused discovery deals. These developments underscore AbCellera's shift toward balancing partner-funded discovery with owned clinical assets amid biotech market dynamics.
AbCellera to Report Second Quarter 2026 Financial Results on August 5, 2026
Are You Looking for a Top Momentum Pick? Why AbCellera Biologics Inc. (ABCL) is a Great Choice
AbCellera Appoints Dr. Lynn Seely to its Board of Directors
Is ABCELLERA BIOLG (ABCL) Stock Outpacing Its Medical Peers This Year?
ABCELLERA BIOLG (ABCL) Surges 7.1%: Is This an Indication of Further Gains?
JAZZ & ABCL Team Up to Develop Next-Generation Solid Tumor Therapies
Jazz Pharmaceuticals Gains Oncology Firepower Through AbCellera Collaboration
Is ABCELLERA BIOLG (ABCL) Outperforming Other Medical Stocks This Year?
Jazz Pharma, AbCellera ink antibody deal worth up to $876 million
Jazz Pharmaceuticals and AbCellera Announce Collaboration to Discover Next-Generation T-cell Engaging Multispecific Antibodies
AbCellera: An AI-Era Antibody Platform Trading For Little More Than Its Cash
AbCellera: Q3 Hot Flashes Data Drop Aside, This Stock Is A Difficult Sell
Wall Street Analysts Think ABCELLERA BIOLG (ABCL) Could Surge 85.59%: Read This Before Placing a Bet
AbCellera Biologics Inc. (ABCL) Presents at Jefferies Global Healthcare Conference 2026 Transcript
AbCellera Appoints Dr. Victor Sandor to its Board of Directors
AbCellera Appoints Dr. Victor Sandor to its Board of Directors
AbCellera Biologics Bets on Hot Flash Antibody as Pipeline Pivot Gains Steam
Has ABCELLERA BIOLG (ABCL) Outpaced Other Medical Stocks This Year?
After Golden Cross, AbCellera Biologics Inc. (ABCL)'s Technical Outlook is Bright
Wall Street Analysts Believe ABCELLERA BIOLG (ABCL) Could Rally 97.28%: Here's is How to Trade